New insights on unique therapeutic potentialities of prostacyclin and prostacyclin synthase. (June 2020)

• Record Type: Journal Article
• Authors: Khan, M.I.; Batool, F.; Kalsoom, F.; Ali, R.; Li, F.; Wang, J.; Haider, Z.; Bilal, M.; Rajput, M.U.; Kazmi, A.; Qiu, B.
• Is Part Of: Materials today chemistry. Volume 16(2020)
• Publication Date: 2020-06
• Subjects: Functions -- Diseases -- Expression -- Regulation -- Therapeutic applications; PGIS Prostacyclin (PGI2) synthase -- hPGIS human PGIS -- PGI Prostaglandin I -- PGH Prostaglandin H -- cDNA clonal DNA -- LOX Lipoxygenase -- AA Amino acid -- Cys Cysteine -- mRNA Messenger RNA -- CYP8A1 Enzyme name -- RO alkoxy radical -- HPETE hydroperoxyeicoatetraenoate -- HETE hydroxyeicoatetraenoate -- Cpd I Culekinin Depolarizing Peptide I -- Cpd II Culekinin Depolarizing Peptide II -- VNTR Variable number of tandem repeats -- NSCLC Non-small lung cancer -- PPAR Peroxisome proliferators activator receptor -- AAV5 Adeno-associated virus 5 -- OEC Olfactory Ensheathing Cells -- Ad adenoviral -- KLF kruppel like factor -- HGFG Hepatocyte growth factor gene -- MCT monocrotaline -- MHC Major histocompatibility complex -- CXCL CXC Ligand -- COX Cycloxygenase -- AAV9CBhPGIS gene -- Epac Exchange protein activated by cyclic AMP -- PKA Protein kinase A -- IP intracelleular loop of human prostacyclin; Chemistry -- Periodicals; Materials -- Research -- Periodicals; Materials science -- Periodicals; Chemistry; Materials -- Research; Electronic journals; Periodicals; 660.282
• DOI: 10.1016/j.mtchem.2020.100258
• Languages: English
• ISSNs: 2468-5194

Abstract

Abstract: Prostacyclin (PGI2) synthase (PGIS) is not only crucial for vascular regulation but also important in driving other activities. Many researchers have reported its significance and highlighted on the critical role of PGIS in terms of health and disease. Besides activating vascular regulation, it inhibits platelet aggregation, prevents the metastasis of cancer, mediates inflammatory response, directly or indirectly regulates the apoptosis, which has been reported to be altered in several diseases. Inadequate expression of this enzyme results in disorders of clotting mechanism, cardiac problems, hypertension, and even is a prognostic factor for cancer patients' survival. Down-regulation in several types of cancers, genetic modifications or mutation of the PGIS gene has been associated with increased risk of thrombosis, stroke, myocardial infarction, and many more complications. Genetic transcription profiling of pulmonary artery hypertensive patients disclosed the diversity of PGIS promoter sequence polymorphisms and discovered the relationship of promoter sequence variants and their expression. Genetically engineered PGIS proved to be very useful for the long-term maintenance and stability of cardiac treatment cell lines. Transfection of the PGIS gene into the liver cells of diabetic rats explained a new direction for the treatment of pulmonary hypertension. Even though significant work has been reported in several studies, no comprehensive review of recent potential insights on PGIS is available in the literature. In this review, we focus on the recent advances on PGI2 and PGIS expression and therapeutic applications in different diseases. Highlights: Pharmacobiochemical and physiological aspects of prostacyclin are discussed. PGIS expression in different diseases are deliberated. Pathological Therapeutic potentialities of prostacyclin and prostacyclin synthase are discussed.